SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - March 2026

Sanofi: Information concerning the total number of voting rights and shares - March 2026

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of €2,424,365,088

Registered office : 46, avenue de la Grande Armée - 75017 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date 



Total number of

issued shares



 		Number of real

voting rights

(excluding treasury shares)		Theoretical number of

voting rights

(including treasury shares)*
31 March 2026 



1,212,182,886		 



1,332,007,927		 



1,346,265,685

* Pursuant to Article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi:

Investor Relations Department

e-mail:



 



 

Attachment



EN
14/04/2026

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - March 2026 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,424,365,088Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry und...

5h / 32m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - MARS 2026 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 424 365 088 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris Date Nombre d’actions composant le capital  Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions ...

5h / 32m 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as t...

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adultsThe latest approval expands Dupixent’s indica...

April 13, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l...

Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée (UCS) pour les enfants âgés de deux à 11 ans est basée sur les données du programme d'études cliniques LIBERTY-CUPID, incluant une extrapolation des données d'efficacité qui montrent que Dupixent a réduit significativement l'activit...

April 13, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi - Combined General Meeting of April 29, 2026 - Availability of ...

Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents   COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29, 2026 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the ...

April 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch